$2.41B in CY2024 Part D spend327K claims · 63K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Upadacitinib used for?
Upadacitinib is a Janus Kinase Inhibitor medication tracked in Medicare Part D.
Is there a generic for Upadacitinib?
No. Upadacitinib is brand-only with no generic equivalents currently in market.
How much does my plan pay for Upadacitinib?
Across 329 Part D plans, Upadacitinib averages $306.03/unit (NADAC). Lowest available: $228.83/unit. Highest in distribution: $460.04/unit.
Is Upadacitinib on the FDA shortage list?
No. Upadacitinib is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.